Rarely do we find a biotech play that`s under the radar after announcing amazing positive results from their cancer test, partnerships and developing the latest technologies in their pipeline to combat the deadliest diseases! This is the reason why Mab Cure Inc. (MBCI) has been one of the hottest biotech mirco/smallcaps around since the company announced study results that show 94% accuracy in confirming Diagnosis of Ovarian Cancer back in July! These results exploded (MBCI) to higher highs. Before we dig deeper into the potential future of (MBCI) , lets focus on the current technicals and why we think (MBCI) i s on high alert at these current levels for a next leg up.
Today (MBCI) closed above the trigger point for the Parabolic SAR and is currently registering a bullish signal. A bearish signal would come if (MBCI) stop limits are triggered at $.71, we see tons of intraday swings and never dropping below that trigger price. Trading above the 13 day MA (Moving Average), this is also considered a bullish indicator because the MA is trending higher and suggesting the buying interest is there, while the MACD is above 0. Again this implies that the underlying moving averages are trending higher and all indicators are aiming higher. See the bullish staircase forming and (MBCI) looking to move higher in our chart below:
Now back to why (MBCI) is a growing biotech company. The timeline of company events suggest (MBCI) is seriously looking to become a major player in the cancer fighting biotech market. Yesterday - MabCure Generates Tumor Specific Antibodies Against Prostate Cancer Which Could Lead To A Blood/Urine Diagnostic Test For Prostate Cancer - "...announced that it has generated a panel of 10 novel monoclonal antibodies (MAbs) against prostate cancer. These MAbs were selected from more than 30,000 MAbs produced by MabCure’s proprietary technology...According to Dr. Gonenne, plans for a clinical study to select the best performing MAbs are underway." Future catalyst to (MBCI) that our TNS investment community needs to keep on high alert! Read full PR here.
October 19, 2010 - MabCure Signs a Collaboration Agreement with a Leading Medical Center in Europe for a Study Aimed at Further Development of a Blood Test for Ovarian Cancer - "...signed a collaboration agreement with Catholic University, K.U. Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe. The agreement reflects the parties’ continued interest in exploring the utility of MabCure’s diagnostic test for ovarian cancer and will assist MabCure in advancing its clinical program. This collaboration follows MabCure’s joint study with Professor Ignace Vergote, a world renowned authority on ovarian cancer, which provided a proof of concept for the ability of MabCure’s antibodies to distinguish between ovarian cancer and benign tumors." Read full PR release here.
July 27th, 2010 - MabCure, Inc. Announces Positive Results For New Ovarian Cancer Diagnostic Blood Test - "...confirmatory study demonstrated the company`s proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure`s serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers." Read full PR release here.
Moreover, seeing the recent developements we are excited about the potential of (MBCI) . We wanted to dig deeper into the potential market for MBCI`s Ovarian Cancer Diagonostic Blood Test. Earlier this year Kalorama Information , a leading publisher of market research in medical markets, including the biotechnology, diagnostics, healthcare, medical device, and pharmaceutical industries for more than 30 years , released a report "In Cancer Diagnostics, the Profit is in Test Services" stated that "Growth rates demonstrate the results of this strategy, according to Kalorama. Average annual revenue growth from 2005 to 2009 for the major cancer test service companies, including Clarient, Genomic Health, Genoptix, and Myriad Genetics, was 60% ; while average annual revenue growth was 14% for the major cancer diagnostics companies during the same period. The research report continued to say that, "Molecular biology is expected to lead to an exponential growth in the number of cancer tests available. Some 25,000 to 30,000 molecular and protein biomarkers may someday become part of the medical toolbox. The mix and match of molecular and protein markers opens the door to a whole new generation of tests. It is as part of this new generation of tests that company developed and in-lab developed cancer tests are aiming to make their mark."
Conclusion: if cancer test services are now growing at 60% per year, they`ll be growing at even a higher percentage per year with the growing cancer cases and demand worldwide for more cancer diagnostics. MabCure has delivered world class results.
MabCure is a company whose vision is to change the perception of cancer as a largely incurable disease. MabCure`s scientists believe that the key to early detection of cancer by antibodies lies in their ability to identify putative tumor markers or tumor-specific antigens (TSA), present on the surface of these cells. Using its proprietary technology, MabCure has created unique and highly specific Mabs against several cancers (e.g. ovarian and prostate carcinomas) which could potentially identify these diseases in their earliest stage. The development of unique and highly specific diagnostic tests could lead to far earlier diagnoses than has ever been possible which, in turn, will bring curing cancers closer to clinical reality.
Beyond the initial focus on developing diagnostic tests, MabCure’s strategic plan calls for the application of its proprietary cancer-specific Mabs in three additional areas:
The imaging of cancer
Immunotherapy of cancer
Discovery of novel cancer markers (tumor specific antigens), which can lead to the development of potent anti-cancer drugs.
In summary, MabCure’s first goal is the development of simple diagnostic tests for the early detection of ovarian, prostate, colorectal and breast carcinomas. Each test will be based upon specific Mabs against a given cancer which should be able to detect unique cancer markers in the blood, urine or other body fluids. Identifying the presence of disease before it disseminates beyond its original site should lead to a 90% cure rate of these cancer patients.
To learn more about this exciting biotech company please visit their website at http://www.mabcure.com/
"Finding Value in the Undervalued"
Become a REAL TRADERS + REAL RESEARCH
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Please remember that this newsletter is intended for commercial advertisement and is for informational purposes only. None of the profiles issued by TooNiceStocks.com, constitutes a recommendation for any investor to purchase or sell any particular security or that any security is suitable for any investor. Any investor should determine whether a particular security is suitable based on the investor’s objectives, other securities holdings, financial situation needs, and tax status.The disclaimer is to be read and fully understood as a opt-in subscriber. Please note well that TooNiceStocks.com employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read
Release of Liability: Through use of this website viewing or using you agree to hold TooNiceStocks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The third party, may have shares and may liquidate it, which may negatively affect the stock price. TooNiceStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TooNiceStocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. TooNiceStocks.com, nor any of its affiliates are not registered investment advisors or a broker dealers. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TooNiceStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. TooNiceStocks.com does not offer such advice or analysis, and TooNiceStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled. TooNiceStocks.com has been compensated forty thousand dollars for one week of commercial advertising, marketing and investor relations contract from our premier strategic corporate communication services for MabCure Inc. by Winning Media. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. From time to time we are compensated for advertising and marketing, full compensation disclosure can be found in our disclaimer in accordance with section 17(b) of the Securities Act of 1933. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Its affilated entities and websites might be compensated and will disclose all compensation on that given entity. In preparing this publication, TooNiceStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TooNiceStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TooNiceStocks.com is not responsible for any claims made by the companies advertised here.
This message was sent by TooNiceStocks, Manhattan NY New York
To contact the sender, reply to this email.
This message may be a newsletter, solicitation or advertisement. Your request
See Too Nice Stocks's website for full disclaimer. Too Nice Stocks may have received compensation for stock picks.